Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 145

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 145
---
 shares, Keystone may resell all, some or none of such Common Stock at any time or from time to time in its discretion and at different prices. As a result, investors who purchase Common Stock from Keystone in this offering at different times will likely pay different prices for those shares of Common Stock, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. See “ Risk Factors-Risks Related to the Keystone Equity Financing-Investors who buy shares of Common Stock from Keystone at different times will likely pay different prices.” Investors may experience a decline in the value of the Common Stock they purchase from Keystone in this offering as a result of future sales made by us to Keystone at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares of Common Stock to Keystone under the Keystone Purchase Agreements, or if investors expect that we will do so, the actual sales of Common Stock or the mere existence of our arrangement with Keystone may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. Because the purchase price per share to be paid by Keystone for the Common Stock that we may elect to sell to Keystone under the Keystone Purchase Agreements, if any, will fluctuate based on the market prices of our Common Stock at the time we make such election, as of the date of this prospectus, it is not possible for us to predict the number of shares of Common Stock that we will sell to Keystone under the Keystone Purchase Agreements, the actual purchase price per share to be paid by Keystone for those shares of Common Stock, or the actual gross proceeds to be raised by us from those sales, if any. As of June 30, 2025, there were 1,194,802 shares of Common Stock outstanding. If all of the 12,500,000 shares of our Common Stock offered for resale by the Selling Securityholder under this prospectus were issued and outstanding as of June 30, 2025, such shares would represent approximately 85.5% of total number of shares of our fully-diluted Common Stock outstanding. The actual number of shares of our Common Stock issuable will vary depending on the then current market price of shares of our Common Stock sold to the Selling Securityholder in this offering. The number of shares of Common Stock ultimately offered for sale by the Selling Securityholder for